Boston Scientific Board Grants Zero‑Cost Deferred Stock Units to Director Amid Mixed Insider Activity and Investor Optimism
Boston Scientific insiders buy zero‑cash deferred stock units, signaling confidence that the firm’s long‑term growth will boost share value.
3 minutes to read


